Cantor Fitzgerald Weighs in on FDMT FY2026 Earnings

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Free Report) - Equities research analysts at Cantor Fitzgerald issued their FY2026 earnings estimates for 4D Molecular Therapeutics in a note issued to investors on Monday, June 9th. Cantor Fitzgerald analyst J. Schimmer anticipates that the company will post earnings of ($2.86) per share for the year. The consensus estimate for 4D Molecular Therapeutics' current full-year earnings is ($2.84) per share.

4D Molecular Therapeutics (NASDAQ:FDMT - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The company reported ($0.86) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.84) by ($0.02).

Other research analysts also recently issued research reports about the stock. Chardan Capital decreased their price target on shares of 4D Molecular Therapeutics from $28.00 to $25.00 and set a "buy" rating for the company in a research note on Friday, May 9th. Barclays cut their price objective on shares of 4D Molecular Therapeutics from $45.00 to $38.00 and set an "overweight" rating on the stock in a report on Friday, May 9th. Bank of America cut their price objective on shares of 4D Molecular Therapeutics from $42.00 to $40.00 and set a "buy" rating on the stock in a report on Monday, March 10th. Royal Bank of Canada cut their price objective on shares of 4D Molecular Therapeutics from $39.00 to $35.00 and set an "outperform" rating on the stock in a report on Monday, March 3rd. Finally, HC Wainwright reissued a "buy" rating and set a $36.00 price objective on shares of 4D Molecular Therapeutics in a report on Monday, March 3rd. One research analyst has rated the stock with a sell rating, two have issued a hold rating and seven have assigned a buy rating to the company. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $29.56.

4D Molecular Therapeutics Stock Down 2.4%

4D Molecular Therapeutics stock traded down $0.11 during trading on Wednesday, reaching $4.39. The stock had a trading volume of 486,407 shares, compared to its average volume of 831,064. 4D Molecular Therapeutics has a 52-week low of $2.24 and a 52-week high of $28.93. The business has a 50 day moving average price of $3.45 and a 200 day moving average price of $4.51. The stock has a market cap of $203.37 million, a PE ratio of -1.54 and a beta of 2.84.

Hedge Funds Weigh In On 4D Molecular Therapeutics

A number of institutional investors have recently modified their holdings of the business. BVF Inc. IL increased its holdings in shares of 4D Molecular Therapeutics by 70.8% in the 1st quarter. BVF Inc. IL now owns 4,561,289 shares of the company's stock valued at $14,733,000 after acquiring an additional 1,890,647 shares during the period. Vanguard Group Inc. increased its holdings in shares of 4D Molecular Therapeutics by 3.4% in the 4th quarter. Vanguard Group Inc. now owns 2,860,508 shares of the company's stock valued at $15,933,000 after acquiring an additional 92,791 shares during the period. Millennium Management LLC increased its holdings in shares of 4D Molecular Therapeutics by 15.0% in the 1st quarter. Millennium Management LLC now owns 1,633,987 shares of the company's stock valued at $5,278,000 after acquiring an additional 213,264 shares during the period. Federated Hermes Inc. increased its holdings in shares of 4D Molecular Therapeutics by 33,131.8% in the 1st quarter. Federated Hermes Inc. now owns 1,250,181 shares of the company's stock valued at $4,038,000 after acquiring an additional 1,246,419 shares during the period. Finally, JPMorgan Chase & Co. increased its holdings in shares of 4D Molecular Therapeutics by 159.5% in the 4th quarter. JPMorgan Chase & Co. now owns 820,069 shares of the company's stock valued at $4,568,000 after acquiring an additional 504,086 shares during the period. 99.27% of the stock is owned by institutional investors and hedge funds.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.